Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Liabilities and Shareholders Equity: 2023-2024

Historic Liabilities and Shareholders Equity for CG Oncology (CGON) over the last 2 years, with Dec 2024 value amounting to $754.8 million.

  • CG Oncology's Liabilities and Shareholders Equity rose 32.12% to $729.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year increase of 53.77%. This contributed to the annual value of $754.8 million for FY2024, which is 278.72% up from last year.
  • Per CG Oncology's latest filing, its Liabilities and Shareholders Equity stood at $754.8 million for FY2024, which was up 278.72% from $199.3 million recorded in FY2023.
  • CG Oncology's 5-year Liabilities and Shareholders Equity high stood at $754.8 million for FY2024, and its period low was $199.3 million during FY2023.
  • Its 2-year average for Liabilities and Shareholders Equity is $477.0 million, with a median of $477.0 million in 2023.
  • Data for CG Oncology's Liabilities and Shareholders Equity shows a peak YoY surged of 278.72% (in 2024) over the last 5 years.
  • Over the past 2 years, CG Oncology's Liabilities and Shareholders Equity (Yearly) stood at $199.3 million in 2023, then skyrocketed by 278.72% to $754.8 million in 2024.